244 related articles for article (PubMed ID: 9751927)
21. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
22. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
[TBL] [Abstract][Full Text] [Related]
23. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
[TBL] [Abstract][Full Text] [Related]
24. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
[TBL] [Abstract][Full Text] [Related]
26. Value of 123I-MIBG Scintigraphy in Paraganglioma.
Milardovic R; Corssmit EP; Stokkel M
Neuroendocrinology; 2010; 91(1):94-100. PubMed ID: 19786729
[TBL] [Abstract][Full Text] [Related]
27. [111IN-octreotide and 123I-MIBG scintigraphy in the diagnosis of small intestinal carcinoid tumors--results of a comparative investigation].
Dresel S; Tatsch K; Zachoval R; Hahn K
Nuklearmedizin; 1996 Apr; 35(2):53-8. PubMed ID: 8721576
[TBL] [Abstract][Full Text] [Related]
28. Octreotide scintigraphy for the detection of paragangliomas.
Kwekkeboom DJ; van Urk H; Pauw BK; Lamberts SW; Kooij PP; Hoogma RP; Krenning EP
J Nucl Med; 1993 Jun; 34(6):873-8. PubMed ID: 8389841
[TBL] [Abstract][Full Text] [Related]
29. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.
Wiseman GA; Kvols LK
Semin Nucl Med; 1995 Jul; 25(3):272-8. PubMed ID: 7570046
[TBL] [Abstract][Full Text] [Related]
30. Strong uptake of 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma.
Manil L; Perdereau B; Barbaroux C; Brixy F
Int J Cancer; 1994 Apr; 57(2):245-6. PubMed ID: 7908895
[TBL] [Abstract][Full Text] [Related]
31. Digital subtraction angiography in the evaluation of chemodectomas.
Vlahos L; Papathanasiou M; Gouliamos A; Dimakakos P; Papavassiliou C
Radiologe; 1988 May; 28(5):233-5. PubMed ID: 2839864
[TBL] [Abstract][Full Text] [Related]
32.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
33. Chemodectomas of the head and neck.
Gonsalves CG; Briant TD
J Can Assoc Radiol; 1979 Jun; 30(2):109-15. PubMed ID: 222768
[No Abstract] [Full Text] [Related]
34. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
35. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
36. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
[TBL] [Abstract][Full Text] [Related]
38. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.
Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H
Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676
[TBL] [Abstract][Full Text] [Related]
39. (111)In-octreotide SPECT-CT in head and neck paragangliomas.
Castillo-Berrio C; Castrillón M; Zelaya F; Ruíz D; Loira F; Nogueiras JM; López A; Guitián R; Outomuro J; Serena A; Campos LM
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):321-4. PubMed ID: 25858499
[TBL] [Abstract][Full Text] [Related]
40. Intraoperative gamma probe detection of head and neck paragangliomas with 111In-pentetreotide: a pilot study.
Filippi L; Valentini FB; Gossetti B; Gossetti F; De Vincentis G; Scopinaro F; Massa R
Tumori; 2005; 91(2):173-6. PubMed ID: 15948547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
